Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Expression of CD11b as an adhesion molecule on neutrophils in children with Kawasaki disease.

Heidari B, Amin R, Kashef S, Alyasin S, Moghtaderi M, Aminshahidi M, Kalani M.

Iran J Allergy Asthma Immunol. 2014 Aug;13(4):265-70.

2.

Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease.

Kobayashi T, Kimura H, Okada Y, Inoue Y, Kobayashi T, Shinohara M, Morikawa A.

Clin Exp Immunol. 2007 Apr;148(1):112-8.

4.

Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.

Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I.

Clin Immunol. 2002 May;103(2):161-8.

PMID:
12027421
5.

Expression of IL-8 in Kawasaki disease.

Asano T, Ogawa S.

Clin Exp Immunol. 2000 Dec;122(3):514-9.

6.

Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.

Sato S, Kawashima H, Kashiwagi Y, Hoshika A.

Int J Rheum Dis. 2013 Apr;16(2):168-72. doi: 10.1111/1756-185X.12082.

PMID:
23773640
7.

Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.

Guo MM, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC.

Allergy. 2015 Mar;70(3):310-8. doi: 10.1111/all.12558. Epub 2015 Jan 14.

8.

[Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].

Liu F, Ding Y, Yin W.

Zhongguo Dang Dai Er Ke Za Zhi. 2013 Dec;15(12):1109-12. Chinese.

PMID:
24342209
9.

Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.

Ye Q, Gong FQ, Shang SQ, Hu J.

Clin Immunol. 2016 Oct;171:25-31. doi: 10.1016/j.clim.2016.08.012. Epub 2016 Aug 9.

PMID:
27519954
10.

Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.

Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.

Clin Exp Immunol. 2013 Dec;174(3):337-44. doi: 10.1111/cei.12182.

11.
12.

Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.

Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.

J Med Assoc Thai. 2002 Nov;85 Suppl 4:S1121-6.

PMID:
12549785
13.

Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.

Ge X, Li CR, Yang J, Wang GB.

Scand J Immunol. 2013 May;77(5):389-97. doi: 10.1111/sji.12022.

14.

Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R.

J Clin Immunol. 2001 May;21(3):193-9.

PMID:
11403226
15.

Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids.

Ballabh P, Simm M, Kumari J, Krauss AN, Jain A, Califano C, Lesser ML, Cunningham-Rundles S.

Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89(1):F76-83.

16.

Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease.

Rasouli M, Heidari B, Kalani M.

Immunol Lett. 2014 Nov;162(1 Pt A):269-75. doi: 10.1016/j.imlet.2014.09.017. Epub 2014 Sep 30.

PMID:
25277751
17.

Serum resistin concentrations in children with Kawasaki disease.

Nozue H, Imai H, Saitoh H, Aoki T, Ichikawa K, Kamoda T.

Inflamm Res. 2010 Nov;59(11):915-20. doi: 10.1007/s00011-010-0202-8. Epub 2010 Apr 27.

PMID:
20422438
18.

Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.

Tse SM, Silverman ED, McCrindle BW, Yeung RS.

J Pediatr. 2002 Apr;140(4):450-5.

PMID:
12006960
19.

Effects of intravenous immunoglobulin on plasma interleukin-10 levels in Kawasaki disease.

Noh GW, Lee WG, Lee W, Lee K.

Immunol Lett. 1998 May;62(1):19-24.

PMID:
9672143
20.

Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.

Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.

J Pediatr. 2006 Jan;148(1):38-43.

PMID:
16423595

Supplemental Content

Support Center